Desloratadine - NDSRI's
References
FAQ's
References
- Hartmann, Fred; Ilner, Wolfgang R., Quantitative estimation of unconjugated cortisol, cortisone, corticosterone, cortexone, and cortexolone by thin-layer chromatography, Research in Experimental Medicine, Volume: 161, Issue: 2, Pages: 165-74, 1973, DOI: (10.1007/BF01855109)
- Villani, Frank J., 8-chloro-6,l 1-dihydro-l l-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[l,2-b]pyridine and its salts, processes for the production thereof and pharmaceutical compositions containing these compounds,WO8503707A1, Aug 29, 1985, Schering Corp., United States
Frequently Asked Questions
What are the steps if unexpected impurities occur during routine quality control testing of Desloratadine batches?
If unexpected Desloratadine impurities are detected, investigations can identify their sources, assess potential risks to patient safety, and implement corrective actions to prevent recurrence.
Can Desloratadine impurities affect the drug's bioavailability in the body?
Some Desloratadine impurities may alter the bioavailability of Desloratadine, affecting its absorption, distribution, metabolism, and excretion in the body.
What are the safety measures to take during the storage of Desloratadine impurities?
Safety measures during the storage of Desloratadine impurities include proper labeling, secure storage conditions, and regular monitoring for any signs of degradation.
What are the uses of Desloratadine impurities?
Desloratadine impurities help in pharmaceutical research, product development, ANDA and DMF filing, quality control (QC), method validation, and stability studies.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.